Grey Wolf HealthTSXV:WOLF -1.69%52 Days Payable is 82.91 as of Mar. 2026, which is 27% below its 10-year median of 113.26. GuruFocus rates TSXV:WOLF with a GF Score™ of 52/100 and a GF Value™ of C$1.10 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Grey Wolf Health ranks worse than 55.34% on this metric.
The historical rank and industry rank for Grey Wolf Health's Days Payable or its related term are showing as below:
TSXV:WOLF'
s Days Payable Range Over the Past 10 Years
Min: 81.37 Med: 113.26 Max: 136.34
Current: 81.37
During the past 5 years, Grey Wolf Health's highest Days Payable was 136.34. The lowest was 81.37. And the median was 113.26.
TSXV:WOLF's Days Payable is ranked worse than 55.34% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs TSXV:WOLF: 81.37
Grey Wolf Health's Days Payable
declined
from Mar. 2025 (96.04) to Mar. 2026 (82.91).
It may suggest that Grey Wolf Healthaccelerated paying its suppliers.
Grey Wolf Health Days Payable Related Terms
Grey Wolf Health Days Payable Historical Data
* Premium members only.
The historical data trend for Grey Wolf Health's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WOLF vs ROL, SCI, FTDR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Grey Wolf Health's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grey Wolf Health Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grey Wolf Health's Days Payable distribution charts can be found below:
* The bar in red indicates where Grey Wolf Health's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Grey Wolf Health's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grey Wolf Health (TSXV:WOLF) has a Days Payable of 82.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grey Wolf Health and its competitors. This is 27% below median its historical median of 113.26. Over the past decade, Grey Wolf Health's Days Payable has ranged from 81.37 to 136.34. According to the industry distribution chart, Grey Wolf Health ranks #513 out of 927 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Grey Wolf Health's Days Payable too high?
Grey Wolf Health's current Days Payable of 82.91 is 27% below median its 10-year median of 113.26. Over the past 10 years, this metric has ranged from a low of 81.37 to a high of 136.34. The Drug Manufacturers industry median Days Payable is 90.38. Grey Wolf Health's value of 82.91 is 8.3% below this industry median. Based on the distribution chart, Grey Wolf Health ranks #513 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grey Wolf Health has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Grey Wolf Health's Days Payable compare to ROL and SCI?
According to the Drug Manufacturers industry distribution chart, Grey Wolf Health ranks #513 out of 927 companies for Days Payable. This places Grey Wolf Health in the lower half of its industry. The industry median Days Payable is 90.38. Grey Wolf Health's value of 82.91 is 8.3% below this benchmark. Historically, Grey Wolf Health's own Days Payable has ranged from 81.37 to 136.34 over the past decade. While the company's 10-year median is 113.26 vs. the industry median of 90.38, Grey Wolf Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grey Wolf Health's current Days Payable of 82.91 is 8.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grey Wolf Health and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grey Wolf Health's current Days Payable is 82.91, which is 27% below median its own 10-year median of 113.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grey Wolf Health stock overvalued right now?
Based on GuruFocus' analysis, Grey Wolf Health (TSXV:WOLF) is currently considered Significantly Overvalued. The stock's GF Value™ is C$1.10, compared to a current price of C$1.75 — trading 59.1% above its estimated fair value. The current Days Payable is 82.91, which is 27% below median its 10-year median of 113.26 and 8.3% below the Drug Manufacturers industry median of 90.38. Grey Wolf Health's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Grey Wolf Health (TSXV:WOLF), the current Days Payable is 82.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grey Wolf Health (TSXV:WOLF) Overvalued in 2026?
Based on GuruFocus' analysis, Grey Wolf Health stock appears to be overvalued.
The current stock price of C$1.75 is trading 59.1% above its estimated GF Value™ of C$1.10.
GuruFocus considers Grey Wolf Health to be Significantly Overvalued.
Key valuation signals for TSXV:WOLF:
Days Payable: 82.91 (27% below median its 10-year median of 113.26)
GF Value™: C$1.10 vs. price of C$1.75 (59.1% above fair value)
Industry Position: 8.3% below the Drug Manufacturers median (#513 of 927)
No single metric tells the full story. See the TSXV:WOLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grey Wolf Animal Health Corp focuses on sourcing, in-licensing, acquiring, and compounding branded and generic products for sale in both animal and human health markets in Canada. The Company operates through two reportable segments: the Animal Health segment, which involves the sale, marketing, and distribution of pharmaceutical, nutraceutical, and consumable products to veterinary clinics across Canada; and the Pharmacy segment, which generates the majority of revenue and focuses on compounding pharmaceuticals for both human and animal health markets.
52GF Score
Get the complete analysis for TSXV:WOLF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WOLF has been successfully added to your 
